Mutations in ERBB2, frequently found in adenocarcinomas were not detected in PSC, whereas mutations in KRAS 59/175 (33.7%) and BRAF 7/175 (4.0%) are comparable to those in ACA [54]. Here, KRAS is linked to adenocarcinoma.